Benralizumab for the prevention of COPD exacerbations

Benralizumab for the prevention of COPD exacerbations

<p><h4>BACKGROUND</h4></p> <p>The efficacy and safety of benralizumab, an interleukin-5 receptor alpha–directed cytolytic monoclonal antibody, for the prevention of exacerbations in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) are n...

Täydet tiedot

Bibliografiset tiedot
Päätekijät: Criner, G, Celli, B, Brightling, C, Agusti, A, Papi, A, Singh, D, Sin, D, Vogelmeier, C, Sciurba, F, Bafadhel, M, Backer, V, Kato, M, Ramírez-Venegas, A, Wei, Y, Bjermer, L, Shih, V, Jison, M, O'Quinn, S, Makulova, N, Newbold, P, Goldman, M, Martin, U, Galathea and Terranova Study Investigators
Aineistotyyppi: Journal article
Kieli:English
Julkaistu: Massachusetts Medical Society 2019

Samankaltaisia teoksia